Bionano Genomics (BNGO) shares fell nearly 8% in recent Thursday trading after the company lowered its Q3 revenue guidance.
The healthcare company slashed its Q3 revenue forecast to between $6.5 million and $6.8 million from a prior outlook of $7.9 million to $8.9 million.
Analysts polled by S&P Capital IQ expect $7.9 million.
Bionano added that it had $23.3 million in cash, cash equivalents, available-for-sale securities, and restricted cash as of Sept. 30, of which $11.4 million was subject to certain restrictions.
The company "has been undertaking a strategic shift in the business that is intended to allow us to become a more capital-efficient business focused on driving utilization and adoption of [optical genome mapping] from our existing installed base, with less emphasis on new placements of our [optical genome mapping] systems. This business transformation may be a factor in revenues coming in lighter than previously anticipated," Bionano Chief Executive Erik Holmlin said in a statement.
Price: 0.39, Change: -0.03, Percent Change: -7.73
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。